Photocure ASA is a Norwegian pharmaceutical company founded in 1993 and listed on Oslo Stock Exchange. The company develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology, targeting key dermatology and oncology markets.

Photocure has three products with sales and marketing approvals:
- Metvix, for the treatment of skin cancer (basal cell carcinoma) and pre-cancerous skin lesions (actinic keratosis)
- Aktilite CL 16 and CL 128, lamps that are intended for use in PDT (photodynamic therapy) in
  combination with Metvix
- Hexvix, for the detection of bladder cancer.

Photocure has its headquarters in Oslo, Norway. The company uses to a large extent external suppliers for functions such as production, R&D, and regulatory matters. Photocure profits from a strong academic network as well as skilled and experienced development staff in-house.

Photocure is also developing photochemical internalisation (PCI), a technology for light-directed drug delivery. PCI Biotech AS, a subsidiary of Photocure, was established in 2000 to ensure an optimal development of the PCI technology.

If you are a media representative and you cannot find the information you need on this web site, please feel free to contact us.

Subscribe to press releases from Photocure.